Jack Kaye Sells 21,167 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director owned 25,996 shares in the company, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 17th, Jack Kaye sold 5,295 shares of uniQure stock. The stock was sold at an average price of $42.57, for a total transaction of $225,408.15.
• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The shares were sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Stock Performance

Shares of QURE stock opened at $41.81 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -12.01 and a beta of 0.90. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The stock’s 50-day moving average price is $30.53 and its 200-day moving average price is $23.86.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Equities research analysts predict that uniQure N.V. will post -3.63 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of the stock. Torren Management LLC purchased a new stake in uniQure during the 4th quarter valued at $28,000. IFP Advisors Inc purchased a new position in uniQure during the fourth quarter worth $48,000. Smartleaf Asset Management LLC bought a new position in uniQure during the fourth quarter valued at $48,000. CIBC Private Wealth Group LLC bought a new position in uniQure during the third quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 906 shares during the period. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on QURE. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Chardan Capital increased their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Royal Bank Of Canada lifted their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, HC Wainwright boosted their target price on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.